Mutations led to resistance by up-regulating beta-lactamase and multi-drug efflux pump.
Antibiotic resistance poses a major threat to public health. Overuse and misuse of antibiotics are generally recognized as the key factors contributing to antibiotic resistance. However, whether non-antibiotic, anti-microbial (NAAM) chemicals can directly induce antibiotic resistance is unclear. We aim to investigate whether the exposure to a NAAM chemical triclosan (TCS) has an impact on inducing antibiotic resistance on Escherichia coli. Here, we report that at a concentration of 0.2 mg/L TCS induces multi-drug resistance in wild-type Escherichia coli after 30-day TCS exposure.
The oxidative stress induced by TCS caused genetic mutations in genes such as fabI, frdD, marR, acrR and soxR, and subsequent up-regulation of the transcription of genes encoding beta-lactamases and multi-drug efflux pumps, together with down-regulation of genes related to membrane permeability. The findings advance our understanding of the potential role of NAAM chemicals in the dissemination of antibiotic resistance in microbes, and highlight the need for controlling biocide applications.
News source: www.sciencedirect.com
Local Organizer of Targeting Phage & Antibiotic Resistance
During the 5th World Congress on Targeting Infectious Diseases: Targeting Phage & Antibiotic Resistance 2018 organized in Florence, Italy in May 17-18, 2018, the Scientific Committee awarded Prof. Richard Novick from the School of Medicine of New York University, USA for all his scientific achievements in the field of phage therapy.
Prof. Richard Novick gave a strategic presentation about “Reincarnation of a staphylococcal pathogenicity island as an antibacterial drone”.
According to Prof. Novick:
“Staphylococcus aureus, long considered a dangerous, antibiotic resistant pathogen, has recently become more virulent, more contagious and more resistant, especially to B-lactams (MRSA) and glycopeptides (VRSA). Today, it causes a wide variety of life-threatening infections, many of which cannot be treated effectively with conventional antibiotics. Consequently, there is an urgent need for new ways to treat these infections, which annually cause some 18,000 deaths in the US.
We have developed a novel non-antibiotic method for treating staphylococcal infections. This method is based on the naturally-occurring, highly mobile staphylococcal pathogenicity islands (SaPIs). The SaPIs are ~15 kb genetic elements that are stably inserted in the staph chromosome but can be induced by “helper” phages to excise and replicate.
[…] Our plans for the future include two major initiatives: Adding new antibacterial modules to the basic system, and expanding the system to other bacterial pathogens.”
Testimonial from Prof. Novick:
“Although I have devoted much of my career to the study of mobile genetic elements in bacteria and have been deeply concerned for many years about the problems of antibiotic resistance, this was my first visit to the world of phage therapy. And it was a wonderful visit – not only did I learn a tremendous amount in a field that I knew only peripherally, but also, I found the scientific talks highly informative and very well presented. […] I anticipate the development of collaborations with several of the scientists that I met at the Congress.”
On behalf of the scientific committee
In few days (May 17-18), you will attend Targeting Phage & Antibiotic Resistance Congress 2018 which will be held at Santa Apollonia Auditorium, in Florence, Italy.
Please click here to access the final agenda.
We remind you that the registration will start at 8:00 on May 17.
Phage Therapy Speed Collaboration
We remind you that you can take part to the Phage Therapy Speed Collaboration which will be organized on May 17 between 17:15 to 18:00.
This session is dedicated to all attendees, academics, start-ups and industrials who are looking for collaboration: each attendee can present his project during one or two minutes to other attendees. If you would like to take part to the Phage Therapy Speed Collaboration, please contact us.
Phage Therapy dinner
The dinner, gathering some attendees and speakers, is organized on May 17 at Hotel Brunelleschi.
Piazza Santa Elisabetta, 3 – 50122 Florence
You can register online here, or on site on May 17.
The poster session will be organized during the coffee breaks and lunch breaks of both days.
Certificate of attendance
The certificate of attendance will be sent to all attendees by email after the congress.
In case of emergency, please contact Prof. Frezza:
tel: 0039 06 7259 4243 or 0039 335 195 6017.
You can also contact us to firstname.lastname@example.org.
A dinner, gathering some attendees and speakers, is organized on May 17 at Hotel Brunelleschi.
Address of Restaurant:
Stemma Restaurant (first floor)
Piazza Santa Elisabetta, 3 – 50122
You can participate to this dinner by booking here.
FLORENCE HOTEL BRUNELLESCHI MAP
The Hotel Brunelleschi is located right in the heart of the pedestrian area within the historical center of Florence, just steps away from the Cathedral and the Signoria Square, and overlooking the Via Calzaiuoli. Check out the exact city center location and details of our elegant hotel with the new Google maps locator tool.
The Scientific Committee published the list of oral communications which will be presented during Targeting Phage & Antibiotic Resistance Congress 2018 in May 17-18, 2018 in Florence.
The scientific committee selected 48 oral communications and already selected 27 poster communications presented during the two-day congress.
To access the agenda, please click here.
Despite the wide availability of antibiotics, infectious diseases remain a leading cause of death worldwide1. In the absence of new therapies, mortality rates due to untreatable infections are predicted to rise more than tenfold by 2050. Natural products (NPs) made by cultured bacteria have been a major source of clinically useful antibiotics. In spite of decades of productivity, the use of bacteria in the search for new antibiotics was largely abandoned due to high rediscovery rates2,3. As only a fraction of bacterial diversity is regularly cultivated in the laboratory and just a fraction of the chemistries encoded by cultured bacteria are detected in fermentation experiments, most bacterial NPs remain hidden in the global microbiome. In an effort to access these hidden NPs, we have developed a culture-independent NP discovery platform that involves sequencing, bioinformatic analysis and heterologous expression of biosynthetic gene clusters captured on DNA extracted from environmental samples. Here, we describe the application of this platform to the discovery of the malacidins, a distinctive class of antibiotics that are commonly encoded in soil microbiomes but have never been reported in culture-based NP discovery efforts. The malacidins are active against multidrug-resistant pathogens, sterilize methicillin-resistant Staphylococcus aureus skin infections in an animal wound model and did not select for resistance under our laboratory conditions.
News source: https://www.nature.com
Queen’s University Belfast
Université Libre de Bruxelles
Eliava Institute of Bacteriophages, Microbiology and Virology
University of Primorska, Faculty of Health Sciences
Universidad Nacional Autonoma de Mexico
University of Lausanne
Istituto Zooprofilattico Sperimentale dell’Abruzzo e del Molise “G. Caporale”
Max Delbrueck Center for Molecular Medicine
Charite University Medicine / Deutsches Rheuma-Forschungszentrum Berlin
G.N. Gabrichevsky Moscow Research Institute for Epidemiology and Microbiology
University of Verona
Comsats institute of information technology, Islamabad Pakistan
Polytechnic University of Marche
Institut de Recherche Biomédicale des Armées
G. Eliava Institute of Bacteriophages, Microbiology and Virology
Institut de Recherche Biomédicale des Armées
Jichi Medical University
Central University of Rajasthan
Institute of Microbiology, Norwegian Armed Forces Joint Medical Services
Astellas Pharma Inc
The University of Chicago
Rakuno Gakuen Univ.
university of Naples Federico II
EA Pharma Co.,Ltd.
Rakuno Gakuen University
ITESM – ITE430714KI0
University of Bath
Biophage Pharma SA
APC Microbiome Ireland, University College Cork
The University of Adelaide
Cellabs Pty Ltd
University of Gothenburg
University of Alabama
Jichi Medical University
Sree Balaji Medical College and Hospital, BIHER-Bharath University
PTC Phage Technology Center GmbH
NYU School of Medicine